Skip to content
VIDEO

Childhood Cancer Immunotherapy Program

VIDEO

New Childhood Brain Cancer Research

VIDEO

37 Years of Dedication

Video

Introducing the Telethon Kids Cancer Centre

VIDEO

Unlocking the key to leukaemia progression in kids

Today Tonight

The new sarcoma research team

video

Meet Finlay

VIDEO

The SJ Elliot Cancer Trial

March 2022

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy

With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.

Children's Cancers Published research Pregnancy and Early Life Immunology Systems Immunology Subsite: Cancer Sarcoma Translational Research
May 2022

The Bone Marrow Microenvironment in B-Cell Development and Malignancy

B lymphopoiesis is characterized by progressive loss of multipotent potential in hematopoi-etic stem cells, followed by commitment to differentiate into B cells, which mediate the humoral response of the adaptive immune system.

Children's Cancers Published research Leukaemia Translational Research
March 2022

Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets

Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited.

Children's Cancers Published research Brain Tumour Research Oncogenic Signalling Laboratory
September 2021

Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy

Little is known about the dynamic biological events that underpin therapeutic efficacy in immune checkpoint blockade (ICB) in cancer, due to the inability to frequently sample tumors in patients. Here, we mapped the transcriptional profiles of 144 responding and non-responding tumors within two mouse models at four time points during ICB. We found that responding tumors displayed on/fast-off kinetics of type-I-interferon (IFN) signaling.

Children's Cancers Published research Computational Biology Sarcoma Translational Research Translational Genetics